The Potential of EGFR-Targeted Agents in Cancer Prevention
The prevention of cancer and its recurrence in high-risk individuals has become an increasingly realistic goal with the introduction of targeted therapies. Like other therapies intended to prevent morbidity and mortality in populations at risk, such as lipid-lowering agents and antihypertensives, cancer-prevention agents are intended for use in generally healthy individuals, and therefore must be well-tolerated. Other challenges associated with the use of agents in cancer prevention, rather than treatment, include the identification of an appropriate dose (the optimal biological dose for advanced disease may not be the optimal dose for early disease or for use in chemoprevention); similarly, the most appropriate schedule and form of administration must be determined. For example, preclinical models of lung cancer chemoprevention suggest that the use of inhaled formulations of retinoids may reduce the systemic side effects associated with chronic oral administration (1).
KeywordsEpidermal Growth Factor Receptor Epidermal Growth Factor Receptor Expression Beta Carotene Growth Factor Receptor Tyrosine Kinase Epidermal Growth Factor Receptor Family
Unable to display preview. Download preview PDF.
- 4.Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 2000;1:12–21.Google Scholar
- 7.Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3’-kinase and distinct from that induced by hypoxia. Cancer Res 2000:60:5879–5886.PubMedGoogle Scholar
- 19.Goss GD, Stewart DJ, Hirte H, et al. Initial results of Part 2 of a Phase I/II pharmacokinetic (PK), pharmacodynamic (PD) and biological activity study of ZD1839 (Iressa): NCIC CTG IND.122. Proc Am Soc Clin Oncol 2002;21:16a, abst 59.Google Scholar
- 21.Herbst RS, Maddox A-M, Rothenberg ML, et al. The selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) is generally well tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial. J Clin Oncol 2002;20:3815–3825.PubMedCrossRefGoogle Scholar
- 23.Fukuoka M, Yano S, Giaccone G, et al. Final results from a Phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;21:298a, abst 1188.Google Scholar
- 24.Kris MG, Natale RB, Herbst RS, et al. A Phase II trial of ZD1839 (‘Iressa’) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxelbased regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002;21:292a, abst 1166.Google Scholar
- 25.Perez-Soler R, Chachoua A, Huberman M, et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:310a, abst 1235.Google Scholar
- 27.Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5. Lyon, FR: IARC Press, 2001. Limited version available from http://www-dep.iarc.fr/globocan/globocan.html 2001; last updated 03/02/2001.Google Scholar
- 28.Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1973–1999 Bethesda, MD: National Cancer Institute, 2002. http://seer.cancer.gov/csr/1973–1999/, 2002.Google Scholar
- 34.Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241–249.PubMedGoogle Scholar
- 47.Cuzick J. Update on new studies in Europe. Eur J Cancer 2002;38 (Suppl 3):abst 20.Google Scholar